ACACA and Hepatic steatosis: In conclusion, we demonstrated that ACC1/2 liver-targeted dual inhibition not only improved hepatic steatosis but also suppressed fibrosis progression in WD-fed MC4R KO mice with severe hepatic steatosis and fibrosis.